Theravance Biopharma (TBPH) EBT (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of EBT data on file, last reported at -$6.5 million in Q1 2026.

• On a quarterly basis, EBT rose 54.24% year-over-year to -$6.5 million in Q1 2026; TTM through Mar 2026 was $116.1 million, a 340.04% increase from a year earlier, with the FY2025 full-year figure at $108.4 million, up 342.95% from the prior year.
• EBT for Q1 2026 stood at -$6.5 million, down from $52.2 million in the prior quarter.
• Over the last five years, EBT for TBPH reached as high as $73.2 million in Q2 2025 and fell as low as -$39.7 million in Q1 2022.
• Historically, EBT has averaged -$5.0 million across 5 years, with a median of -$10.4 million in 2024.
• Across the five-year window, EBT plunged 78.21% in 2024 and soared 684.08% in 2025, its largest moves.
• Year by year, EBT stood at -$14.3 million in 2022, then jumped by 64.82% to -$5.0 million in 2023, then plunged by 78.21% to -$8.9 million in 2024, then surged by 684.08% to $52.2 million in 2025, then tumbled by 112.39% to -$6.5 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$6.5 million in Q1 2026, $52.2 million in Q4 2025, and -$2.9 million in Q3 2025.